← Human Trials & Peer-Reviewed Studies
The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers
Plain-language guide to PMID 9471423 (1997): double-blind randomized controlled trial study of Octreotide, pancreatitis (after the acute phase).
Key Facts
- PMID
- 9471423
- Journal
- Gut
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- van Berge Henegouwen MI et al. (5 authors)
- DOI
- 10.1136/gut.41.6.758
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Octreotide in the context of pancreatitis (after the acute phase), published as a randomized controlled trial.
The influence of octreotide on this complication is doubtful.
Who Took Part
By PubMed's age tags, the people studied were adults, men only.
Eight healthy male volunteers (mean age 22.5 years) participated in this double blind, placebo controlled study.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Octreotide, so expectations could not easily colour the readings.
Some participants received a placebo instead of Octreotide, giving a reference point.
In the crossover set-up each of the participants took both Octreotide and the comparison in turn, acting as their own control.
The methods mention a period of one week.
This protocol was repeated after one week, in a crossover design.
From the gastric emptying curves, lag time, t50, and postlag emptying rate were measured.
MCTT was measured using the hydrogen breath test.
What Was Measured
Topics PubMed links to this paper include Cholecystokinin, Gastric Emptying, Gastrointestinal Agents, Gastrointestinal Motility, Octreotide, Pancreaticoduodenectomy and Postoperative Complications.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Octreotide in people with pancreatitis (after the acute phase) over one week.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1997 (Gut), a journal based in England.
More context: the Octreotide compound page, Pancreatitis (after the acute phase) research.
Our Notes on the Compound
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.